Drugs / MT-3534
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06482346 | Aug 2024 → Jul 2025 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-3534 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06482346 ↗ |
| Route | Intravenous | “Intravenous (IV)” NCT06482346 ↗ |